To amend title VII of the Public Health Service Act to strengthen the mental health workforce, and for other purposes.
Summary
HR7787 is an early-stage bill authorizing a mental health provider loan forgiveness program. It has been referred to committee with no companion bill, zero appropriations, and minimal legislative momentum. Market impact is negligible at this stage. Real market data shows AMN Healthcare at $20.65, up 12.6% over 30 days, and Centene at $53.22, up 62.55% over 30 days, driven by other factors unrelated to this procedural bill.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR7787 is a procedural authorization bill at the earliest committee referral stage with no funding and no Senate companion.
- 2.Market impact is negligible; no stock movement can be attributed to this bill based on available data.
- 3.Both AMN Healthcare and Centene have seen strong recent gains (+12.6% and +62.55% respectively over 30 days) driven by other market factors, not this legislation.
Market Implications
No near-term market implications. HR7787 is a procedural health workforce authorization bill with zero appropriations, no legislative momentum, and no identifiable path to enactment in the current session. Investors should monitor committee hearings or a companion Senate bill introduction as triggers for further analysis. Current price action in AMN Healthcare ($20.65, +12.6% monthly) and Centene ($53.22, +62.55% monthly) reflects completely unrelated market dynamics.
Full Analysis
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Authorizes a voluntary loan deferment and forgiveness program for mental health professionals working full-time for 5 years in designated shortage areas; the program is unfunded in this bill and requires separate appropriations to operate.
Who must act
Secretary of Health and Human Services, contingent on future appropriations from Congress
What happens
No direct economic effect until and unless appropriations are passed; the program would increase supply of mental health providers in shortage areas, potentially reducing demand for temporary staffing solutions over a multi-year horizon.
Stock impact
AMN Healthcare provides temporary staffing of healthcare professionals including mental health providers; an increased supply of permanent providers in shortage areas could moderately reduce demand for locum tenens and temporary placements over the long term, but this bill is procedural and provides no funding.
Market Impact Score
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Second Chance Mental Health Access Act of 2026
TRIWEST HEALTHCARE ALLIANCE CORP: $929M Department of Veterans Affairs Contract
Mental Health in Aviation Act of 2025
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.
Accelerating Medical Treatments for Serious Mental Illness
This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.